Construction Therapeutics’ aleniglipron, a once-daily oral GLP-1 drug, led to a mean 16% weight reduction measured at 44 weeks. Primarily based on these outcomes, the biotech is making ready for Section 3 testing anticipated to start within the second half of this yr.
The put up Construction Therapeutics Oral GLP-1 Weight problems Drug Achieves ‘Injectable-Like Efficacy’ in Section 2 Check appeared first on MedCity Information.
